Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial
Nature Medicine - Results from this single-arm cohort of the BFAST trial showed that the clinical efficacy of entrectinib in patients with ROS1-positive NSCLC, selected using liquid biopsies, is...
nature.com